Dbv Technologies
Clinical trials sponsored by Dbv Technologies, explained in plain language.
-
Peanut patch trial for toddlers: a safer future for allergy kids?
Disease control Recruiting nowThis study tests a skin patch called DBV712 that delivers a tiny amount of peanut protein to help 1-3 year olds with peanut allergy become less sensitive over time. The main goal is to check if the patch is safe to use for 6 months. About 480 children will take part, and half wil…
Phase: PHASE3 • Sponsor: DBV Technologies • Aim: Disease control
Last updated May 26, 2026 11:31 UTC
-
Peanut patch program offers continued hope for allergic kids
Disease control AVAILABLEThis program provides continued access to the Viaskin peanut patch for children aged 2 and older who have peanut allergy and previously took part in a DBV712 study. The patch is designed to help desensitize the immune system to peanuts, reducing the risk of severe allergic reacti…
Sponsor: DBV Technologies • Aim: Disease control
Last updated May 26, 2026 11:30 UTC